CC16 in Childhood and Resilience to Persistent Asthma into Adult Life (Supplement)

项目总结 回应NOT-AI-20-031[特别关注的通告：严重急性呼吸系统综合症冠状病毒2 (SARS-CoV-2)和冠状病毒病2019(新冠肺炎)“]并根据父母赠款的范围， 本补充的目的是确定俱乐部细胞分泌蛋白(CC16)在提供 对新冠肺炎的韧性。CC16是一种由SCGB1A1基因编码的同源二聚体肺炎蛋白， 主要由远端呼吸道的俱乐部细胞产生，在循环中很容易测量到。 我们父母资助的中心假设是CC16通过调节 对呼吸道感染的易感性和炎症反应。此外，由于分泌CC16的俱乐部细胞 是表达血管紧张素转换酶2(ACE2)的主要呼吸道细胞类型之一，有可能是 -通过感染俱乐部细胞-SARS-CoV-2可以影响它们的生存和/或分泌机制，进而影响 CC16的生产。在这里，我们假设CC16在易感性和宿主炎症中起关键作用。 应对SARS-CoV-2，并提出以下具体目标： 具体目的：确定循环CC16与血管内皮细胞瘤的存在和临床进展的关系。 新冠肺炎。 在这项初步研究中，我们将收集住院患者和门诊患者的临床数据和生物标本。 图森班纳大学医学中心的新冠肺炎。根据大流行的动态，我们 估计我们将招募75-125名住院患者和100-200名门诊患者。此外，我们还将招聘一名 对照组(目标病例：对照比例为2：1)。来自这些参与者的数据将用于比较 对照组、新冠肺炎门诊患者和新冠肺炎患者三组的循环CC16水平 住院病人。此外，还将检测CC16的循环缺陷，以预测随后的临床应用。 疾病的发展。

PROJECT SUMMARY In response to NOT-AI-20-031 [“Notice of Special Interest: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”] and in line with the scope of the parent grant, the goal of this supplement is to determine the role of Club cell secretory protein (CC16) in providing resilience to COVID-19. CC16 is a homodimeric pneumoprotein that is encoded by the SCGB1A1 gene, mainly produced by Club cells in the distal airways, and readily measured in circulation. The central hypothesis of our parent grant is that CC16 exerts protective effects in the lungs by modulating susceptibility and inflammatory responses to airway infections. In addition, because CC16-secreting Club cells are among the main airway cell types expressing Angiotensin-Converting Enzyme 2 (ACE2), it is plausible that – by infecting Club cells – SARS-CoV-2 can affect their survival and/or secretory machinery, and in turn impact production of CC16. Here, we postulate that CC16 plays a critical role in susceptibility and host inflammatory responses to SARS-CoV-2 and propose the following specific aim: Specific Aim - To determine the relation of circulating CC16 to the presence and clinical progression of COVID-19. In this pilot study, we will collect clinical data and biospecimens from both inpatients and outpatients with COVID-19 at Banner University Medical Center – Tucson. Depending on the dynamics of the pandemic, we estimate that we will recruit between 75-125 inpatients and 100-200 outpatients. In addition, we will recruit a group of controls (with a target case:control ratio of 2:1). Data from these participants will be used to compare circulating levels of CC16 across the three groups of controls, COVID-19 outpatients, and COVID-19 inpatients. In addition, circulating deficits of CC16 will be tested for prediction of subsequent clinical progression of disease.